Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease Review Abstract Purpose Acute myeloid leukemia (AML) is a heterogeneous group of hematologic malignancies defined increasingly by recurrent molecular and cytogenetic abnormalities. KMT2A rearrangements and NPM1 mutations identify biologically distinct leukemias that frequently rely on menin-dependent
Tag: revumenib
